As shown in Fig. 1e,f, LLGL2low/SLC7A5low showed longer survival than LLGL2high/SLC7A5high and a positive trend of longer survival compared with other combination groups in ERα-positive breast cancer patients receiving adjuvant tamoxifen therapy. Here, ESR1 is linked to breast carcinoma.